PHAT

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

DEFA14A - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

DEF 14A - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NYDate: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDTManagement to participate in one-on-one meetings throughout t

S-8 - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

Barclays upgraded Phathom Pharmaceuticals from Equal Weight to Overweight and set a new price target of $18.00

SCHEDULE 13G - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

10-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidance; operating profitability expected beginning in Q3 2026 and for FY 2026 Management to host conference call today, February 26, 2026, at 8:00 a.m. EST FLORHAM PARK, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pha

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MADate: Monday, March 2, 2026Company Presentation: 10:30 am ESTManagement to participate in one-on-one meetings throughout the conference Jefferies Biotech on the Beach Summit in Miami, FLDate: Tuesday, March 10, 2026 Management to participate in one-on-one meetings throughout the

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion o

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST. Company management will also participate in one-on-one meetings during the conference, which will run from February 11-12, 2026, in New York, NY. To access the live webcast and archived recordings of the event, visit the News & Events section of the Phathom website at https://inves

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

4 - Phathom Pharmaceuticals, Inc. (0001783183) (Issuer)

8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

424B5 - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per share and the pre-funded warrants are being sold at a price of $15.999 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded war